 |
TWINRIX, the only hepatitis A and hepatitis B combination vaccine available in the United States, is available on a dosing schedule at 0, 7, 21-30 days, followed by a booster dose at 12 months. TWINRIX may still be administered according to the original 3 dose schedule, which is an initial dose followed by doses at 1 and 6 months following the initial dose.
Choose the course of protection
that fits
your patient’s needs
TWINRIX accelerated dosing offers significant
protection at day 37
A prospective, open-label, randomized comparative study of 496 healthy adults. TWINRIX (Day 0, 7, 21-30 followed by booster dose Month 12) versus hepatitis A vaccine [Havrix® (Hepatitis A Vaccine, Inactivated)] (Day 0, Month 12) and hepatitis B vaccine (Engerix-B® [Hepatitis B Vaccine (Recombinant)]) (Day 0, Month 1, 2, 12). [1]
*This difference of 19.76% [95% CI for the difference is 10.16% to 28.99%] is statistically significant (p<0.001).
Please see Important Safety Information for TWINRIX.
Please see complete Prescribing Information for TWINRIX.
TWINRIX accelerated dosing delivers a
sustained immune response ![[1]](images/ref1.gif)
A prospective, open-label, randomized comparative study of 496 healthy adults. TWINRIX (Day 0, 7, 21-30 followed by booster dose Month 12) versus hepatitis A vaccine [Havrix® (Hepatitis A Vaccine, Inactivated)] (Day 0, Month 12) and hepatitis B vaccine (Engerix-B® [Hepatitis B Vaccine (Recombinant)]) (Day 0, Month 1, 2, 12). [1]
|
| |
Immunize with confidence
- TWINRIX on the accelerated schedule has a similar safety profile to the standard schedule and monovalent vaccines [1]
- Approximately 52.5 million doses of TWINRIX have been distributed worldwide 12 [2]
 |
| |
Important Safety Information
TWINRIX is contraindicated in people with hypersensitivity to any component of the vaccine, including yeast and neomycin.
In clinical trials with TWINRIX, the most common solicited adverse events were:
| • soreness at the injection site | • headache |
| • redness at the injection site | • fatigue |
They were mild and self-limiting and did not last more than 48 hours.
As with any vaccine, rare adverse events may occur. (See Adverse Reactions section of the Prescribing Information for TWINRIX for other potential side effects.)
As with any vaccine, TWINRIX may not protect 100% of individuals receiving the vaccine.
Please see complete Prescribing Information for TWINRIX.
TWINRIX and Tip-Lok are registered trademarks of GlaxoSmithKline.
Manufactured by GlaxoSmithKline Biologicals, Rixensart, Belgium
Distributed by GlaxoSmithKline, Research Triangle Park, NC 27709
|
|
